Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

Cipla Limited on Wednesday announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...